跳转至内容
Merck
所有图片(1)

Key Documents

更多文件

1448956

USP

霉酚酸酯

United States Pharmacopeia (USP) Reference Standard

别名:

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H31NO7
CAS号:
128794-94-5
分子量:
433.49
MDL號碼:
MFCD00867568
分類程式碼代碼:
41116107
PubChem物質ID:
329750505
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

mycophenolate

製造商／商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

15-25°C

SMILES 字串

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChI 密鑰

RTGDFNSFWBGLEC-SYZQJQIISA-N

基因資訊

human ... IMPDH1(3614) , IMPDH2(3615)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

生化／生理作用

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

Y0000489

霉酚酸酯, European Pharmacopoeia (EP) Reference Standard

Y0000519

吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard

1448967

Mycophenolate Mofetil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1448978

Mycophenolate Mofetil Related Compound B, United States Pharmacopeia (USP) Reference Standard

1448989

Mycophenolate sodium, United States Pharmacopeia (USP) Reference Standard

Y0002200

Mycophenolate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2776

Mycophenolate Mofetil Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material, pkg of 100 mg

PHR3211

Mycophenolate Sodium, pharmaceutical secondary standard, certified reference material

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

儲存類別代碼

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 4

1 of 4

Sigma-Aldrich

Sigma-Aldrich

SML0936

特立氟胺

富马酸二甲酯 certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Supelco

50744

富马酸二甲酯

他克莫司 United States Pharmacopeia (USP) Reference Standard

USP

1642802

他克莫司

Rapamycin VETRANAL®, analytical standard

Supelco

37094

Rapamycin

A D Goralczyk et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12(10), 2601-2607 (2012-07-21)
Liver transplant recipients are at high risk of developing acute and chronic renal failure. Moreover, introduction of the model for end-stage liver disease (MELD) score for primary allocation of liver grafts favors patients with pretransplant kidney dysfunction, which in turn
John Seal et al.
Transplantation, 99(3), 623-628 (2014-08-26)
There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.
Andrew Bentall et al.
Transplantation, 98(10), 1089-1096 (2014-06-10)
ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than positive crossmatch kidney transplantations (+XMKTxs). This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year surveillance biopsies and the clinical outcomes in
K Budde et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)
This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure
P Satwani et al.
Leukemia, 29(2), 448-455 (2014-06-19)
The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门